过氧化物酶体增殖物激活受体γ Pro12Ala基因多态性与慢性肾脏病危险因素的关系  

Relationship between peroxisome proliferation-activated receptor-gamma Pro12Ala gene polymorphism and risk factors of chronic kidney disease

作　　者：刘峰[1] 张颖莹[1] 齐华林[1] 张新天[1] 王俊[1] 江薇[1] 庄守纲[1] 王奕[1] 

机构地区：[1]同济大学附属东方医院肾内科,上海200120

出　　处：《新乡医学院学报》2014年第5期328-332,共5页Journal of Xinxiang Medical University

基　　金：上海市浦东新区重点学科项目(编号:PWZxk2010-02)

摘　　要：目的探讨过氧化物酶体增殖物激活受体γ（PPARγ）Pro12Ala基因多态性与慢性肾脏病（CKD）的关系。方法选取CKD患者178例（CKD组）和正常体检健康对照者271例（对照组）,应用聚合酶链反应-限制性片段长度多态性技术检测PPARγPro12Ala基因突变,测定研究对象的血压、体质量指数（BMI）、尿白蛋白/尿肌酐、24 h尿蛋白定量、血肌酐、空腹血糖（FBG）、血脂、肾小球滤过率、颈动脉斑块（CAP）数量和颈动脉内膜中层厚度（CIMT）等临床指标。结果 CKD组与对照组患者Pro12Pro、Pro12Ala基因型分布频率比较差异无统计学意义（P〉0.05）,2组患者Pro、Ala等位基因分布频率比较差异亦无统计学意义（P〉0.05）。大量蛋白尿组与蛋白尿组CKD患者Pro12Ala基因型、Ala等位基因频率比较差异均无统计学意义（P〉0.05）,CKD 2~5期与CKD 1期患者Pro12Ala基因型、Ala等位基因频率比较差异均无统计学意义（P〉0.05）。Pro12Pro基因型CKD患者与Pro12Ala基因型患者BMI、FBG、血压、总胆固醇、高密度脂蛋白-胆固醇比较差异均无统计学意义（P〉0.05）,但Pro12Pro基因型患者24 h尿蛋白定量、血肌酐、三酰甘油、低密度脂蛋白-胆固醇、CAP数量和CIMT均高于Pro12Ala基因型患者,差异有统计学意义（P〈0.05）。结论 PPARγPro12Ala基因多态性与蛋白尿、血脂异常、血管硬化等CKD危险因素有相关性。Ala等位基因可能减少CKD发生发展的高危因素,成为CKD的保护基因。Objective To investigate the relationship between peroxisome proliferation-activated receptor-gamma （PPART） Prol2Ala gene polymorphism and risk factors for chronic kidney disease（CKD）. Methods One hundred and seventy-eight patients with CKD（ CKD group） and two hundred and seventy-one healthy controls（ control group） were selected in this study. PPAR＇,/Prol2Ala gene polymorphism was determined by polymerase chain reaction-restricted fragments length polymorphism. Clinical characteristics of blood pressure, body mass index （BMI） , urinary albumin/urine creatinine, urine protein in 24 hours, serum creatinine （ SCr）, fasting blood glucose （ FBG）, blood lipoprotein, glomerular filtration rate （ GFR）, carotid artery plaque（CAP） amount and carotid intima-media thickness （CIMT） were measured. Results There was no significant difference in the Prol2Pro and Prol2Ala genotype frequency between CKD group and control group（ P 〉0.05 ）. There was no significant difference in the Pro and Ala allele frequencies between CKD group and control group （ P 〉 0. 05 ）. There was no significant difference in the Prol2Ala genotype frequency and Ala allele frequencies between mass proteinuria group and proteinuria group（ P 〉0.05 ）. There was no significant difference in the Prol2Ala genotype frequency and Ala allele frequen- cies between the CKD patients in stage 1 and stage 2 - 5 （ P 〉 0.05 ）. The levels of BMI, FBG, blood pressure, total cholesterol, high-density lipoproteins in patients with Prol2Pro genotype were similar to those in patients with Prol2Ala genotype （ P 〉 0. 05 ）. Meanwhile, the levels of urine protein in 24 hours, SCr, triacylglycerol, low-density lipoproteins, CAP and CIMT in pa- tients with Pro l 2Pro genotype were significantly higher than those in patients with Pro l2Ala genotype （P 〈 0. 05 ）. Conclusions The Prol2Ala polymorphism of PPAR7 gene is correlated to the risk factors（ urine protein, abnormal lipid metabolism, atherosclerosis�

关 键 词：慢性肾脏病 基因多态性 过氧化物酶体增殖物激活受体Γ 

分 类 号：R692[医药卫生—泌尿科学]